Survodutide for Obesity: Phase 3 SYNCHRONIZE-1 Results

Key Finding Survodutide 6.0 mg once weekly led to -13.0% mean weight reduction vs -5.4% with placebo at week 76 in a phase 3 trial of 725 adults with obesity, with 71.9% of participants achieving at least 5% weight loss.

Glucagon-like peptide-1 (GLP-1) receptor agonists have reshaped the landscape of obesity treatment, but the search continues for mechanisms that offer additional leverage. Survodutide — an investigational dual agonist of the glucagon receptor and the GLP-1 receptor — represents a different pharmacological approach: instead of relying solely on incretin signaling, it adds glucagon receptor activation, which may contribute additional energy expenditure through increased thermogenesis and hepatic lipid metabolism.

The first phase 3 results for survodutide were published this week in the New England Journal of Medicine [PMID 42253238]. The SYNCHRONIZE-1 trial randomized 725 adults with obesity (or overweight with at least one obesity-related complication, excluding diabetes) in a 1:1:1 ratio to once-weekly subcutaneous survodutide titrated to 3.6 mg or 6.0 mg, or to placebo. All groups received lifestyle counseling. The trial ran for 76 weeks, with coprimary endpoints of percent weight change and the proportion of participants achieving at least 5% weight reduction.

The data

At baseline, the mean body weight across groups was 108.8 kg and mean BMI was 37.9. By week 76:

3.6 mg survodutide: −12.2% mean weight change (95% CI, −13.6 to −10.8)
6.0 mg survodutide: −13.0% (95% CI, −14.4 to −11.6)
Placebo: −5.4% (95% CI, −6.9 to −4.0)

Weight reduction of at least 5% was achieved by 72.6% of participants in the 3.6-mg group, 71.9% in the 6.0-mg group, and 46.3% in the placebo group (P<0.001 for both comparisons). The absolute separation from placebo — roughly 7 to 8 percentage points beyond what lifestyle modification alone produced — is consistent with the pattern seen across the GLP-1 class, though the trial did not include an active comparator.

Safety and tolerability

Gastrointestinal symptoms were the most common adverse events, reported in 80.9% of the 3.6-mg group, 89.7% of the 6.0-mg group, and 47.9% of the placebo group. These were described as typically mild to moderate in severity, consistent with the tolerability profile of other agents in the incretin class. No deaths were reported in any group.

What makes survodutide different

The dual glucagon-GLP-1 mechanism is the distinguishing feature of this agent. Glucagon receptor agonism increases resting energy expenditure and promotes lipid oxidation — an effect that GLP-1 monotherapy does not produce. Earlier phase 2 data had suggested that the added glucagon activity could translate into greater weight loss than GLP-1-selective agents, and the SYNCHRONIZE-1 results now provide phase 3 confirmation of the signal.

Whether the glucagon component adds value beyond weight loss — for example, in hepatic outcomes or metabolic rate — will depend on the broader SYNCHRONIZE program, which includes participants with type 2 diabetes and metabolic dysfunction-associated steatohepatitis.

What remains open

These are 76-week efficacy data on weight, not cardiovascular outcomes. Phase 3 programs for obesity drugs now routinely include longer-term safety extensions and, in some cases, dedicated cardiovascular outcome trials. Survodutide’s SYNCHRONIZE program is ongoing, and results in other populations will clarify whether the dual mechanism offers advantages in glycemic control, liver fat reduction, or metabolic health beyond the weight effect alone.

For now, the headline is straightforward: a glucagon-GLP-1 dual agonist can produce clinically meaningful weight loss at 76 weeks in a phase 3 setting, and the safety profile aligns with the established tolerability constraints of the incretin class.